Generic Muse Availability
MUSE (alprostadil - suppository;urethral)
Manufacturer: MEDA PHARMS
Approval date: November 19, 1996
Strength(s): 0.125MG, 0.25MG, 0.5MG, 1MG [RLD]
Has a generic version of Muse been approved?
No. There is currently no therapeutically equivalent version of Muse available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Muse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method and composition for treating erectile dysfunction
Issued: March 23, 1999
Inventor(s): Kock; Nils G. & Lycke; Gerhard
Lipophilic active substance composition and its use in a new method of treating erectile dysfunction by administration thereof, optionally together with a hydrophilic vehicle and optionally an antibacterial agent into the urethra.Patent expiration dates:
- March 23, 2016✓✓
- March 23, 2016
- Muse suppository Consumer Information (Wolters Kluwer)
- Muse injectable and transurethral Consumer Information (Cerner Multum)
- Muse Advanced Consumer Information (Micromedex®)
- Muse Urethral Advanced Consumer Information (Micromedex®)
- Alprostadil Consumer Information (Wolters Kluwer)
- Alprostadil suppository Consumer Information (Wolters Kluwer)
- Alprostadil injectable and transurethral Consumer Information (Cerner Multum)
- Muse Micro Advanced Consumer Information (Micromedex®)
- Muse Micro Urethral Advanced Consumer Information (Micromedex®)
- Alprostadil Intraurethral, Intravenous, Intracavernosal Advanced Consumer Information (Micromedex®)
- Alprostadil Intravenous Advanced Consumer Information (Micromedex®)
- Alprostadil Urethral Advanced Consumer Information (Micromedex®)
- Alprostadil AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|